Sarepta Therapeutics’ Strategic Alliance with Arrowhead Pharmaceuticals Secures Future Growth
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...